iBio, Inc.

NASDAQ:IBIO

Biotechnology

Healthcare
$0.85 +0.00%

+$0.00 today

Market cap
$59.75M
Beta
1.29
P/E (TTM)
-3.6
EPS (TTM)
-$0.32
52W Low $0.78High $3.82

Volume 0.84M

Average 0.81M

IBIO Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

iBio, Inc.NASDAQ: IBIO

Capital Expenditures · Q4 FY2026 · quarter ended Jun 2026

Capital expenditures grows, but more slowly than its trailing trend

Q4 FY2026 capital expenditures of $19K (cash outflow) rose 1800.0% year over year, behind the +3512.5% change in trailing-twelve-month capital expenditures. Sequentially, it rose 72.7% from the prior quarter. Over 3 fiscal years it compounded at -53.5% a year.

Context

  • Capital expenditures amounted to 578.0% of revenue in FY2026, up 574.0 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +1800.0% toward the trailing-twelve-month pace of +3512.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$19K+72.7% QoQ
Last fiscal yearJun 2026
-$578K+3512.5% YoY
LTMJun 2026
-$578K+3512.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1800.0%——
1 year+3512.5%——
3-year CAGR-53.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2026
(578K) USD
Year-over-year change
-3512.5%

Capital Expenditures vs competitors

How IBIO compares with its peers on the latest reported figures

  • IBIO's LTM Jun 2026 capital expenditures of $578K is the largest of the 4 companies compared; the peer median is $0.
  • Its year-over-year change of +3512.5% is the highest of 2, against a peer median of -80.3%.
  • Capital expenditures amounts to 578.0% of revenue for IBIO, versus a peer median of 0.0%.
IBIO Competitors Peer median
Capital Expenditures for IBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBIOiBio, Inc.LTM Jun 2026$578K +3512.5%-53.5%578.0%
BOLDBoundless Bio, Inc.LTM Mar 2026$495K -80.3%-20.0%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 ———
RLYBRallybio CorporationLTM Mar 2026$0 ——0.0%
Peer median (excluding IBIO) $0-80.3%-20.0%0.0%

Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Net Income(29.51M)(65.01M)(24.91M)(18.38M)(33.04M)
Depreciation & Amortization3.79M1.38M1.25M291K88K
Deferred Income Tax00000
Stock-Based Compensation4.38M4.39M2.04M1.53M1.37M
Change in Working Capital3.24M5.87M(3.17M)479K2.52M
Accounts Receivables4.21M6.1M00(65K)
Inventory(3.87M)(1.02M)000
Accounts Payables1.24M(625K)(1.49M)1.83M2.22M
Other Working Capital1.66M1.41M(1.68M)(1.35M)364K
Other Non-Cash Items(15.32M)22.93M6.23M773K5.84M
Operating Cash Flow(37.8M)(30.44M)(18.55M)(15.3M)(23.22M)
Capital Expenditures(7.33M)(5.74M)(210K)(16K)(578K)
Acquisitions (Net)0(692K)000
Purchases of Investments(7.12M)000(42.3M)
Sales of Investments13.62M10.84M000
Other Investing Activities(4.3M)2.6M1.12M758K10.88M
Investing Cash Flow(5.13M)7.01M906K742K(32M)
Debt Repayment(5.83M)(9.13M)(1.14M)(771K)(6.63M)
Common Stock Issued77K11.49M25.52M9.7M109.58M
Common Stock Repurchased0(39K)(7K)00
Dividends Paid00000
Other Financing Activities(50K)(22K)197K0105K
Financing Cash Flow(5.8M)2.3M24.49M8.93M103.05M
Effect of Forex Changes(6M)33K00(18K)
Net Change in Cash(54.73M)(21.09M)6.85M(5.63M)47.83M
Free Cash Flow(45.13M)(36.17M)(18.76M)(15.32M)(23.8M)

iBio, Inc.

NASDAQ:IBIO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.